DARE - Company ID 0001401914
Dare Bioscience, Inc. trades as DARE. In its fiscal 2025 annual report the company posted revenue of $1.03M, up 10429.4% from the prior year and net income of -$13.40M. This page tracks Dare Bioscience, Inc. through 740 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 13 fiscal years Dare Bioscience, Inc.'s revenue grew from $625.00K to $1.03M, a compound annual growth rate of 3.9%. Net profit margin compressed from -87.8% to -1300.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| 253G2 | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
The largest companies sharing Dare Bioscience, Inc.'s SEC industry classification (pharmaceutical preparations).
Dare Bioscience, Inc. reported revenue of $1.03M for fiscal year 2025, an increase of 10429.4% year over year.
In its latest fiscal year Dare Bioscience, Inc. reported a net loss of $13.40M.